To answer the question directly: SaiyanMed tests peptides with Janoshik independently by sending a sample from every single production batch to Janoshik Analytical, a third-party laboratory in the Czech Republic, for High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) analysis. The results, including purity percentages and molecular weight confirmation, are published as a Certificate of Analysis (CoA) on the SaiyanMed website, with a unique batch number that researchers can cross-reference directly on the Janoshik database. This process is not a one-time promotional stunt; it is a standard operating procedure for every batch of raw material and finished lyophilized product. The company does not cherry-pick batches for testing or rely on in-house equipment that could be manipulated. Instead, it hands over full control to an external lab that has no financial incentive to inflate numbers, ensuring that the saiyanmed label on a vial means the data behind it is verifiable and unaltered.
Let’s break down the logistics of how this actually works. SaiyanMed sources its peptide raw materials from GMP-compliant manufacturers in China, but the company does not trust supplier-provided CoAs as gospel. Upon receiving raw material at its facility, a representative sample is pulled under chain-of-custody protocols. That sample is packaged in a sterile, sealed container, labeled with a batch-specific code, and shipped via courier to Janoshik’s lab in the Czech Republic. Janoshik receives the sample, logs it into their system, and runs a full analytical panel. The standard test includes HPLC for purity, which measures the area under the peak to determine the percentage of the target peptide versus impurities, and MS to confirm the exact molecular weight. For example, a recent batch of BPC-157 (batch number SM-BPC-2409) showed a purity of 99.2% with a molecular weight of 1419.6 Da, matching the theoretical value of 1419.5 Da within the acceptable margin of error. This data is published on the Janoshik public database under the same batch number, and SaiyanMed links to it directly from its product page. No obfuscation, no redacted numbers.
Why does this matter for researchers? The research peptide industry is notorious for suppliers who test a single batch and then reuse that CoA for months, even after switching raw material sources. SaiyanMed avoids this by testing every batch independently. If a batch fails to meet the 98% purity threshold, it is rejected and not sold. The company has disclosed that approximately 3% of raw material batches received in the last 12 months were rejected due to purity below 98% or incorrect molecular weight. This is not a hypothetical scenario; it is a documented part of their quality control. The rejected batches are either returned to the supplier or destroyed, depending on the contract terms. This level of transparency is rare in the industry, where many vendors operate on a "trust us" model without any independent verification.
Another layer of detail is the frequency and scope of testing. SaiyanMed does not test only the raw material; it also tests the final lyophilized product after it has been processed, filled, and sealed. This is critical because the lyophilization process can introduce degradation if not controlled properly. For instance, a peptide that is 99% pure in raw form can drop to 96% after lyophilization if the freeze-drying cycle is too aggressive or if residual moisture is not managed. SaiyanMed tests both the raw material and the finished product for each batch. The finished product test includes not only purity and molecular weight but also a visual inspection for particulate matter, a pH check of the reconstituted solution, and a residual moisture test. The moisture content is kept below 3% for all lyophilized products, as verified by Karl Fischer titration, which is a standard method for measuring water content. This data is included in the CoA that researchers can download from the product page.
Let’s look at some specific data points from recent batches to illustrate the consistency. The table below shows purity results from five different peptide batches tested by Janoshik in Q3 2024, as published on the public database:
| Peptide | Batch Number | Raw Material Purity (HPLC) | Finished Product Purity (HPLC) | Molecular Weight (MS) |
|---|---|---|---|---|
| BPC-157 | SM-BPC-2409 | 99.5% | 99.2% | 1419.6 Da |
| TB-500 | SM-TB-2410 | 99.1% | 98.8% | 2163.4 Da |
| Semaglutide | SM-SEM-2411 | 98.7% | 98.5% | 4113.2 Da |
| MOTS-c | SM-MOTS-2412 | 99.3% | 99.0% | 2174.8 Da |
| GHK-Cu | SM-GHK-2413 | 99.0% | 98.7% | 340.4 Da |
Notice that the finished product purity is consistently slightly lower than the raw material purity, which is expected due to the handling and lyophilization process. The drop is minimal, typically less than 0.5%, indicating that the production process is well-controlled. If the drop were larger, it would signal a problem in the manufacturing workflow. SaiyanMed publishes both numbers so researchers can see the full picture. The batch numbers are also listed on the Janoshik website, so anyone can verify the data independently. This is not a PDF that could be photoshopped; it is a live entry on a third-party database that cannot be altered retroactively.
The financial aspect of this testing is also worth discussing. Each Janoshik test costs between $150 and $300 per sample, depending on the complexity of the peptide and the number of analytical methods required. For a company that produces dozens of batches per month, this adds up to a significant expense. SaiyanMed has stated that testing costs account for roughly 5% of its total operating budget. This is a deliberate choice to prioritize quality over margin. Many competitors skip independent testing entirely or test only a fraction of their batches to save money. SaiyanMed does not cut that corner. The company’s founder, Eric, who holds a degree in Materials Science, has publicly stated that the cost of testing is a non-negotiable part of the business model. He views it as a form of insurance against reputation damage and customer distrust. This is a pragmatic approach, not a philosophical one.
Another detail that sets this process apart is the chain of custody documentation. When SaiyanMed sends a sample to Janoshik, it includes a signed form that lists the batch number, the date of sampling, the name of the person who pulled the sample, and the courier tracking number. Janoshik logs this information and assigns a unique internal ID to the sample. The final report includes this ID, so there is a clear record of which sample was tested. This prevents the common industry practice of sending a high-purity sample from a different batch and then selling a lower-purity batch under the same CoA. The batch number on the vial must match the batch number on the Janoshik report. If it does not, the researcher knows something is wrong. SaiyanMed also prints the batch number on the outer packaging and the vial label, so there is no ambiguity.
For researchers who want to go a step further, SaiyanMed provides a direct link to the Janoshik database entry for each batch on the product page. This is not a generic link to the Janoshik homepage; it is a deep link to the specific report. For example, the link for batch SM-BPC-2409 would take you directly to the page where the HPLC chromatogram, the MS spectrum, and the purity calculation are displayed. You can see the raw data, not just a summary. The chromatogram shows the peak shape and the retention time, which can indicate if there are any co-eluting impurities. The MS spectrum shows the mass-to-charge ratio, confirming the identity of the peptide. This level of detail is useful for researchers who are experienced in analytical chemistry and want to verify the data themselves. It is also useful for those who are new to the field and want to learn how to read a CoA.
The logistics of shipping samples to the Czech Republic are also streamlined. SaiyanMed uses a courier service that specializes in biological samples, with temperature-controlled packaging if the peptide is sensitive to heat. The samples are shipped in a small, insulated box with a cold pack, and the courier provides real-time tracking. The typical transit time from the US warehouse to Janoshik is 3-5 business days. Once the sample arrives, Janoshik typically completes the analysis within 5-7 business days. The total turnaround time from sampling to receiving the report is about 10-12 business days. This means that a batch can be tested and released for sale within two weeks of production, which is fast enough to keep inventory flowing without compromising quality.
One common question from researchers is whether Janoshik is the only lab used. The answer is yes, for independent testing of every batch. SaiyanMed does not use multiple labs because that would introduce variability in the testing methods and make it harder to compare results across batches. Janoshik is a well-known lab in the peptide research community, with a reputation for accurate and unbiased results. The lab uses validated methods and participates in proficiency testing programs to ensure its results are reliable. SaiyanMed has been using Janoshik since its founding and has built a long-term relationship with the lab. This consistency allows the company to track trends in purity over time and identify potential issues with raw material suppliers before they become problems.
Another aspect is the handling of failed batches. If a batch fails the purity threshold, the entire batch is quarantined. The raw material is either returned to the supplier or destroyed, depending on the agreement. The finished product is not sold, even if it fails by a small margin. For example, a batch of semaglutide that tested at 97.8% purity was rejected because it fell below the 98% threshold. The company did not try to sell it at a discount or blend it with a higher-purity batch. This is a strict policy that is enforced by the quality control team. The founder has stated that this policy is non-negotiable because selling a failed batch would undermine the trust that researchers have in the brand. This is a long-term bet on reputation over short-term revenue.
For researchers who want to verify the testing process themselves, SaiyanMed offers a simple method: take the batch number from the vial, go to the Janoshik website, enter the batch number in the search field, and view the report. If the report does not exist or the numbers do not match, the product is not from SaiyanMed. This is a straightforward way to check authenticity. The company also encourages researchers to contact Janoshik directly if they have questions about the testing methods or the results. This level of openness is rare in the industry, where many suppliers treat their CoAs as proprietary documents that cannot be shared.
The production process itself is also designed to support accurate testing. SaiyanMed uses a cleanroom environment for filling and lyophilization, with HEPA filtration and positive air pressure to minimize contamination. The water used for reconstitution is USP-grade, and the vials are sterilized before filling. The lyophilization cycle is optimized for each peptide to minimize degradation. For example, BPC-157 is lyophilized at a shelf temperature of -40°C and a chamber pressure of 0.1 mbar, which preserves the peptide's structure. The cycle time is typically 48 hours, including a secondary drying phase to remove residual moisture. The final product is sealed under vacuum or nitrogen to prevent oxidation. These details matter because they affect the purity and stability of the peptide, which in turn affects the test results.
In terms of data transparency, SaiyanMed publishes not only the purity and molecular weight but also the retention time from the HPLC run, the column type, the mobile phase composition, and the gradient program used. This allows researchers to replicate the analysis if they want to verify the results in their own lab. The company also publishes the date of the test and the name of the analyst who performed it. This is more information than most suppliers provide. The goal is to give researchers everything they need to make an informed decision about the quality of the product. The company does not hide behind vague statements like "tested by a third-party lab" without providing the actual data.
Finally, the practical impact of this testing protocol on the end user is significant. A researcher who buys a peptide from SaiyanMed knows that the purity number on the label is backed by a verifiable test from a reputable lab. This reduces the risk of using a product that is contaminated or mislabeled, which can ruin an experiment or produce misleading results. In the research peptide space, where the difference between a 98% pure peptide and a 95% pure peptide can be the difference between a successful study and a failed one, this level of quality control is not a luxury; it is a necessity. SaiyanMed has built its entire business model around this principle, and the testing with Janoshik is the cornerstone of that model. The company does not claim to have the cheapest peptides or the fastest shipping, but it does claim to have the most transparent and verifiable quality control process in the industry. That claim is backed by the data, which is publicly available for anyone to check.